Chantix -- "Pfizer Drug Tied to Heart Risks" by Thomas M. Burton
Pfizer Inc.'s smoking-cessation drug Chantix was linked to a 72% increase in risk of cardiovascular problems, including stroke and congestive heart failure, according to a new analysis of medical studies.
Researchers looked at 14 clinical trials of the drug, involving 8,216 patients, and concluded that the medicine "was associated with a significantly increased risk of serious adverse cardiovascular events" compared with patients given a placebo. Read more here.
The 2011 Canadian Medical Association Journal paper documenting Chantix (varenicline) dangers
"Chantix Unsuitable for First-Line Smoking Cessation Use, Study Finds" Science Daily Nov. 2, 2011
"Suicidal Behavior and Depression in Smoking Cessation Treatments" Moore T, etal, PLOS One, Nov. 2, 2011
"Prescription Drugs Associated with Reports of Violence Towards Others" Moore T. etal PLOS One, Dec 15, 2010
Fair Use Notice:
These links may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is used for non-profit educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. Any copyright owner who objects to the use of their copyrighted material should send an e-mail to EmpathicTherapy@hotmail.com